Elite in Small Cell Lung Cancer (SCLC)

Manuel C. Domine

Madrid, MD, ES 
Elite in Small Cell Lung Cancer (SCLC)
Madrid, MD, ES 
OverviewLocationsClinical Research

Overview

Manuel Domine practices in Madrid, Spain. Mr. Domine is rated as an Elite expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 98 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 4 clinical trials in the study of Small Cell Lung Cancer (SCLC).

Gender
Male

Locations

Madrid, MD, Spain
Other Locations
Valencia, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.
A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Nivolumab
Study Phase: Phase 3
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed
Study Phase: Phase 2
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Placlitaxel, Atezolizumab
Study Phase: Phase 2
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drug: Brigatinib
Study Phase: Phase 2
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Carboplatin, Nivolumab
Study Phase: Phase 2
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
Enrollment Status: Terminated
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Pemetrexed
Study Phase: Phase 2
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drug: Atezolizumab+Bevacizumab
Study Phase: Phase 2
A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance
A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance
Enrollment Status: Completed
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel, Pemetrexed
Study Phase: Phase 2
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Paclitaxel, Carboplatin
Study Phase: Phase 2
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
Enrollment Status: Completed
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naïve and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis
Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naïve and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Enrollment Status: Completed
Publish Date: June 27, 2022
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Diagnostic test
View 15 Less Clinical Trials

97 Total Publications

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial.
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Domine's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile